公开(公告)号：US12115178B2

公开(公告)日：2024-10-15

申请号：US17557772

申请日：2021-12-21

Applicant: Flagship Pioneering Innovations V, Inc.

Inventor： Steven John Taylor ,  Mi-Jeong Kim ,  Kathleen Nudel ,  Timothy F. Briggs ,  Koji Yasuda ,  Leonard Buckbinder ,  Bernard Lanter ,  Spencer Cory Peck ,  Cheri Snedeker ,  Angela She ,  Jessica Alexander ,  Anna Liang ,  Jenny Liu ,  Dinara Gunasekera ,  David Arthur Berry ,  John Patrick Casey, Jr. ,  Amir H. Moarefi

IPC: A61K31/7036 ,  A61K9/00 ,  A61K31/191 ,  A61K31/196 ,  A61K31/353 ,  A61K31/519 ,  A61P37/06

CPC classification number: A61K31/7036 ,  A61K9/0053 ,  A61K31/191 ,  A61K31/196 ,  A61K31/353 ,  A61K31/519 ,  A61P37/06

Abstract: Disclosed herein are acylated active agents and methods of their use, e.g., for modulating an autoimmunity marker or for treating an autoimmune disorder.

公开(公告)号：US20240277647A1

公开(公告)日：2024-08-22

申请号：US18654220

申请日：2024-05-03

Applicant: Johnson & Johnson Consumer Inc.

Inventor： Aliaksandr Zhuk ,  Anthony Geonnotti ,  Dara Miller ,  Jennifer Li ,  Nikoleta Batchvarova ,  Nicole Comito

IPC: A61K31/192 ,  A61K9/00 ,  A61K9/06 ,  A61K31/19 ,  A61K31/191 ,  A61K31/366 ,  A61K31/7004 ,  A61K47/10 ,  A61K47/32 ,  A61K47/34 ,  A61P17/10 ,  A61P31/04

CPC classification number: A61K31/192 ,  A61K9/0014 ,  A61K9/06 ,  A61K31/19 ,  A61K31/191 ,  A61K31/366 ,  A61K31/7004 ,  A61K47/10 ,  A61K47/32 ,  A61K47/34 ,  A61P17/10 ,  A61P31/04 ,  A61K2300/00

Abstract: Provided are methods and compositions suitable for treating acne, disrupting a biofilm, and/or killing bacteria contained in a biofilm. Certain methods comprise applying to a surface having a biofilm a composition comprising a first alpha hydroxy acid, a second alpha hydroxy acid, and a polyhydroxy acid.

公开(公告)号：US20240207209A1

公开(公告)日：2024-06-27

申请号：US18226711

申请日：2023-07-26

Applicant: Neurocentria, Inc.

Inventor： Guosong Liu ,  Fei Mao ,  Qifeng Sun

IPC: A61K31/191 ,  A61K31/14 ,  A61K33/00 ,  A61K33/06 ,  A61K33/26 ,  A61K45/06

CPC classification number: A61K31/191 ,  A61K31/14 ,  A61K33/00 ,  A61K33/06 ,  A61K33/26 ,  A61K45/06

Abstract: Provided herein is a method of using threonate to alter cellular physiology, such as neuronal physiology. A method of the present disclosure may include providing to a medium comprising a cell, a threonate-containing compound, or a precursor thereof, to increase the concentration of threonate in the medium, where the increased concentration of threonate is sufficient to increase the concentration of magnesium in the cell. Also provided is a method that includes administering a threonate-containing compound, or a precursor thereof, to an individual, to increase synaptic density in the brain and/or to treat a neurological disorder, e.g., cognitive impairment. The threonate-containing compound of the present disclosure does not include magnesium threonate.

公开(公告)号：US11986582B2

公开(公告)日：2024-05-21

申请号：US17511348

申请日：2021-10-26

Applicant: NxStage Medical, Inc.

Inventor： Goetz Friederichs ,  William K. Weigel ,  Dennis M. Treu ,  Jeffrey H. Burbank ,  James M. Brugger ,  Keith David J. Wheeler ,  Scott W. Newell

IPC: A61M1/16 ,  A61K31/191 ,  A61M1/14 ,  A61M1/36 ,  B01F21/20 ,  C02F9/00 ,  F15B1/04 ,  C02F1/20 ,  C02F1/28 ,  C02F1/42 ,  C02F1/44 ,  C02F103/02 ,  C02F103/04

CPC classification number: A61M1/1666 ,  A61K31/191 ,  A61M1/1524 ,  A61M1/154 ,  A61M1/155 ,  A61M1/1561 ,  A61M1/1562 ,  A61M1/1565 ,  A61M1/1658 ,  A61M1/166 ,  A61M1/362227 ,  A61M1/36224 ,  A61M1/36225 ,  A61M1/362261 ,  A61M1/362262 ,  A61M1/362265 ,  B01F21/20 ,  C02F9/00 ,  F15B1/04 ,  A61M1/1563 ,  A61M1/362263 ,  A61M2205/3317 ,  A61M2205/3368 ,  A61M2205/502 ,  A61M2205/6054 ,  A61M2205/6072 ,  C02F1/20 ,  C02F1/283 ,  C02F1/42 ,  C02F2001/425 ,  C02F2001/427 ,  C02F1/44 ,  C02F2103/026 ,  C02F2103/04 ,  C02F2209/05 ,  C02F2209/445 ,  F15B2201/315 ,  Y02A50/30

Abstract: A medicament preparation system includes a water purification module and a medicament proportioning module that is interoperable with a replaceable fluid circuit. The fluid circuit includes a purified water inlet, a product medicament outlet, and a plurality of pumping tube segments. At least a first concentrate container is connected by at least a portion of the fluid circuit to the product medicament output and a first concentration measurement sensor station is positioned in a flow path. A controller is programmed to calculate iteratively a concentration of a first concentrate from the first concentrate container and the purified water from a signal generated by the first concentration measurement sensor station and to regulate one or both of a first pumping actuator engaged with the first pumping tube segment and a second pumping actuator engaged with the second pumping tube segment, responsively to the concentration of the first concentrate and water.

公开(公告)号：US11969439B1

公开(公告)日：2024-04-30

申请号：US18520172

申请日：2023-11-27

Applicant: EXELA PHARMA SCIENCES, LLC

Inventor： John Maloney ,  Aruna Koganti ,  Phanesh Koneru

IPC: A61K33/06 ,  A23L33/16 ,  A23L33/175 ,  A61K9/00 ,  A61K31/095 ,  A61K31/191 ,  A61K31/198 ,  A61K31/401 ,  A61K31/405 ,  A61K31/4172 ,  A61K33/00 ,  A61K33/241 ,  A61K33/28 ,  A61K33/36 ,  A61K47/02 ,  A61J1/14

CPC classification number: A61K33/06 ,  A23L33/16 ,  A23L33/175 ,  A61K9/0029 ,  A61K31/095 ,  A61K31/191 ,  A61K31/198 ,  A61K31/401 ,  A61K31/405 ,  A61K31/4172 ,  A61K33/00 ,  A61K33/241 ,  A61K33/28 ,  A61K33/36 ,  A61K47/02 ,  A23V2002/00 ,  A61J1/1412

Abstract: The subject matter described herein is directed to stable L-cysteine compositions for injection, comprising: L-cysteine or a pharmaceutically acceptable salt thereof and/or hydrate thereof in an amount from about 10 mg/mL to about 100 mg/mL; Aluminum in an amount from about 1.0 parts per billion (ppb) to about 250 ppb; cystine in an amount from about 0.01 wt % to about 2 wt % relative to L-cysteine; pyruvic acid in an amount from about 0.01 wt % to about 2 wt % relative to L-cysteine; a pharmaceutically acceptable carrier, comprising water; headspace O2 that is less than 1.0%; dissolved oxygen present in the carrier in an amount from about 0.01 parts per million (ppm) to about 1 ppm, wherein the composition is enclosed in a single-use container having a volume of from 10 mL to 100 mL. Also described are compositions for a total parenteral nutrition regimen and methods for their use.

公开(公告)号：US20240066075A1

公开(公告)日：2024-02-29

申请号：US18244685

申请日：2023-09-11

Applicant: MarvelBiome, Inc.

Inventor： Jothi Amaranath Govindan ,  Elamparithi Jayamani ,  Priti H. Chatter ,  Mukesh Chatter

IPC: A61K35/742 ,  A61K31/191 ,  A61K35/745 ,  A61K35/747 ,  A61P27/02 ,  G01N33/50

CPC classification number: A61K35/742 ,  A61K31/191 ,  A61K35/745 ,  A61K35/747 ,  A61P27/02 ,  G01N33/5008 ,  C12R2001/125

Abstract: Methods and uses of compositions (e.g. comprising one or more microbial strains, comprising one or more metabolites (e.g. derived from microbial strains or sources other than microbial strains (e.g. synthetically derived)), comprising one or more components, or a combination thereof) for treating eye disorders are disclosed.

公开(公告)号：US20240041790A1

公开(公告)日：2024-02-08

申请号：US18382741

申请日：2023-10-23

Applicant: SurgiWipe LLC

Inventor： Michael YAYAC ,  JAVAD PARVIZI ,  HARRY BRITTAIN ,  JEONGEUN CHO ,  Aradhna SAXENA ,  MAYANK PARMAR

IPC: A61K9/70 ,  A61K31/191 ,  A61K9/107 ,  A61K31/455 ,  A61K36/61 ,  A61K47/10

CPC classification number: A61K9/70 ,  A61K31/191 ,  A61K9/107 ,  A61K31/455 ,  A61K36/61 ,  A61K47/10

Abstract: An antiseptic composition for penetrating and treating the dermis and/or pilosebaceous follicle of a mammal, said antiseptic composing comprising: (a) a sebostatic agent for reducing sebum production to prevent clogging of skin pores; (b) a barrier-forming emollient for forming a protective barrier film to aid said dermis in maintaining moisture and to shield said dermis from the environment; and (c) an antiseptic agent.

公开(公告)号：US11850303B2

公开(公告)日：2023-12-26

申请号：US16949376

申请日：2020-10-27

Applicant: Uqora, Inc.

Inventor： Spencer Gordon

IPC: A61K9/06 ,  A61K9/02 ,  A61K31/191 ,  A61K31/7016 ,  A61K31/702 ,  A61K33/40 ,  A61K35/747

CPC classification number: A61K9/06 ,  A61K9/02 ,  A61K31/191 ,  A61K31/702 ,  A61K31/7016 ,  A61K33/40 ,  A61K35/747

Abstract: A gel and suppository and method to provide the gel and the suppository, are disclosed herein. The gel comprising: between 50 and 150 millimolar of lactic acid concentrate; and between 0.5 and 10 millimolar of hydrogen peroxide concentrate. The suppository comprising: between 22.5 and 67.5 milligrams of lactic acid concentrate; and between 1 and 20 milligrams of hydrogen peroxide concentrate.

公开(公告)号：US20230398158A1

公开(公告)日：2023-12-14

申请号：US18251657

申请日：2021-11-04

Applicant: Lactobio A/S

Inventor： Charlotte VEDEL ,  Katja Billekop OLSEN ,  Søren KJÆRULFF ,  Sigurd CHRISTENSEN

IPC: A61K35/744 ,  A61K31/194 ,  A61K31/191 ,  A61K31/60 ,  A61K9/00 ,  A61P17/10

CPC classification number: A61K35/744 ,  A61K31/194 ,  A61K31/191 ,  A61K31/60 ,  A61K9/0014 ,  A61P17/10

Abstract: The present invention relates to a composition for improvement of a skin condition comprising a supernatant produced from fermentation of a bacteria wherein the supernatant comprises at least 3 metabolites produced by the bacteria during fermentation wherein the at least 3 metabolites include at least one of succinic acid, 2-Hydroxyisocaproic acid, azelaic acid and/or salicylic acid, 5 and wherein at least one of succinic acid, 2-Hydroxyisocaproic acid, azelaic acid, and/or salicylic acid is/are produced by fermentation of a lactic acid bacteria.

公开(公告)号：US20230248721A1

公开(公告)日：2023-08-10

申请号：US18091145

申请日：2022-12-29

Applicant: Children's Medical Center Corporation

Inventor： Debra Auguste ,  Marsha A. Moses ,  Peng Guo

IPC: A61K31/4965 ,  A61K31/191 ,  A61K31/4365 ,  G01N33/574 ,  A61K9/14 ,  A61K31/429 ,  C12Q1/6886 ,  A61K47/54

CPC classification number: A61K31/4965 ,  A61K9/14 ,  A61K31/191 ,  A61K31/429 ,  A61K31/4365 ,  A61K47/555 ,  C12Q1/6886 ,  G01N33/57415 ,  A61K2121/00 ,  C12Q2600/158 ,  G01N2333/70525

Abstract: A method of detecting triple negative breast cancer (TNBC) is provided. Overexpression of ICAM-1 is linked to an increased risk of TNBC. A composition of matter is also provided that binds an anti-ICAM~1 antibody to a nanoparticle. The composition may be used as an imaging agent and/or a therapeutic targeting agent. A therapeutically active molecule may be bound to the composition to provide targeted therapy.